Skip to content
Mirtazapine
Remeron (mirtazapine) is a small molecule pharmaceutical. Mirtazapine was first approved as Remeron on 1996-06-14. It is used to treat depressive disorder in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 2A, alpha-2A adrenergic receptor, 5-hydroxytryptamine receptor 2C, alpha-2C adrenergic receptor, and alpha-2B adrenergic receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
mental disordersD001523
Trade Name
FDA
EMA
Remeron, Remeron soltab (generic drugs available since 2003-01-24)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mirtazapine
Tradename
Company
Number
Date
Products
REMERONOrganonN-020415 RX1996-06-14
2 products, RLD
REMERON SOLTABOrganonN-021208 RX2001-01-12
3 products, RLD
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
mirtazapineANDA2023-06-20
remeron remeronsoltabNew Drug Application2021-11-18
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
depressive disorderEFO_1002014D003866F32.A
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N06: Psychoanaleptics
— N06A: Antidepressants
— N06AX: Other antidepressants in atc
— N06AX11: Mirtazapine
HCPCS
No data
Clinical
Clinical Trials
7 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E11——5——5
Type 1 diabetes mellitusD003922EFO_0001359E10——1——1
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMIRTAZAPINE
INNmirtazapine
Description
Mirtazapine is a benzazepine and a tetracyclic antidepressant. It has a role as an alpha-adrenergic antagonist, a serotonergic antagonist, a histamine antagonist, an anxiolytic drug, a H1-receptor antagonist and a oneirogen.
Classification
Small molecule
Drug classtricyclic compounds
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CN1CCN2c3ncccc3Cc3ccccc3C2C1
Identifiers
PDB—
CAS-ID61337-67-5
RxCUI15996
ChEMBL IDCHEMBL654
ChEBI ID6950
PubChem CID4205
DrugBankDB00370
UNII IDA051Q2099Q (ChemIDplus, GSRS)
Target
Agency Approved
HTR2A
HTR2A
ADRA2A
ADRA2A
HTR2C
HTR2C
ADRA2C
ADRA2C
ADRA2B
ADRA2B
Organism
Homo sapiens
Gene name
HTR2A
Gene synonyms
HTR2
NCBI Gene ID
3356
Protein name
5-hydroxytryptamine receptor 2A
Protein synonyms
5-HT2 receptor, 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled, serotonin 5-HT-2A receptor, Serotonin receptor 2A
Uniprot ID
Q5T8C0
Mouse ortholog
Htr2a (15558)
5-hydroxytryptamine receptor 2A (P35363)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Remeron - Organon
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 8,975 documents
View more details
Safety
Black-box Warning
Black-box warning for: Mirtazapine, Remeron remeronsoltab
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
784 adverse events reported
View more details